MOUNTAIN VIEW, Calif.—Perlegen Sciences Inc. announced a new four-year research pact with Pfizer whereby researchers from both companies will conduct whole-genome studies involving DNA samples from clinical trials.
"We have continued to expand our relationship with Pfizer over time," says Paul Cusenza, senior VP of Perlegen "This latest collaboration will extend until December 2009 and is a [significant amount of research] in whole-genome and replication studies to identify genes that are associated with major diseases, as well as those that predict patient response to certain medicines."